PD-0166285

N/A

Report date: 2026/05/13 20:02:10

NME

Base Information

Drug NamePD-0166285

Drug Alias NamePD-0166285PD-166285

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsSerine/threonine-protein kinase WEE1 inhibitorsTyrosine-protein kinase SRC inhibitors +[5]

TargetsEpidermal growth factor receptor erbB1Platelet-derived growth factor receptor betaFibroblast growth factor receptor 1 +[5]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesParke-Davis Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesParke-Davis Gmbh

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A